Epub 2009 Jan 7.Aliment Pharmacol Ther. 2006 Sep 1;24(5):851-8. doi: 10.1111/j.1365-2036.2006.03026.x.Breynaert C, Ferrante M, Fidder H, Van Steen K, Noman M, Ballet V, Vermeire S, Rutgeerts P, Van Assche G.Am J Gastroenterol. 2011 Jul;2(3):133-139. doi: 10.1136/fg.2010.003558. COVID-19 is an emerging, rapidly evolving situation. 2007;67(12):1703-23. doi: 10.2165/00003495-200767120-00005.BioDrugs. eCollection 2016.Drugs. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease Eur J Gastroenterol Hepatol. Epub 2020 May 26.Sandberg KC, Lucien JN, Stoll D, Yanney E, Mezoff A.Pediatr Qual Saf. 2017 Oct;65(4):430-431. doi: 10.1097/MPG.0000000000001535.Adv Ther. CONCLUSIONS: Rapid infliximab infusions of ≤1-h duration are not associated with increased risk of infusion reaction when compared to standard 2- to 3-h infusions in selected patients who previously tolerated three to four standard infusions. Results: Seventy-five subjects with IBD were included in the study.
2016 Nov;33(11):1947-1963. doi: 10.1007/s12325-016-0406-6. Rapid infusion of infliximab is safe and well tolerated, with no increase in infusion-related reactions. Patient satisfaction was addressed through a survey following the implementation of the rapid infusion protocol.
A new study sought to evaluate the safety and outcomes of continuing rapid infusion protocols after a switch to biosimilar infliximab.
Name must be less than 100 characters Five hundred and twenty-two rapid infliximab infusions were provided to patients. This site needs JavaScript to work properly. 2020 Jul;52(1):54-72. doi: 10.1111/apt.15779. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000.J Pediatr Gastroenterol Nutr. 2009 Jan;21(1):71-5. doi: 10.1097/MEG.0b013e3283081afe.Principi M, Losurdo G, La Fortezza RF, Lopolito P, Lovero R, Grillo S, Bringiotti R, Ierardi E, Di Leo A.J Gastrointestin Liver Dis. 2011 Apr;106(4):778-85. doi: 10.1038/ajg.2011.61. 2006 Feb 15;23(4):451-63. doi: 10.1111/j.1365-2036.2006.02786.x.Hommes DW, Oldenburg B, van Bodegraven AA, van Hogezand RA, de Jong DJ, Romberg-Camps MJ, van der Woude J, Dijkstra G; Dutch Initiative on Crohn and Colitis (ICC).Al-Ani AH, Prentice RE, Rentsch CA, Johnson D, Ardalan Z, Heerasing N, Garg M, Campbell S, Sasadeusz J, Macrae FA, Ng SC, Rubin DT, Christensen B.Aliment Pharmacol Ther. Epub 2011 Mar 15.Bermejo F, López San Román A, Algaba A, van Domselaar M, Carneros JA, Rivero M, Piqueras B, Valer MP.Gastroenterol Hepatol. Unable to load your collection due to an error Unable to load your delegates due to an error Diltiazem (Cardizem) Infusion Protocol **** Scan to pharmacy and place in orders section of chart*** A physician’s order is required for implementation of the protocol. There were no acute or delayed infusion reactions. 2016 Feb;61(2):589-96. doi: 10.1007/s10620-015-3893-4. 2019 Jan 21;4(1):e131. doi: 10.1097/pq9.0000000000000131. Patients who have Infliximab over 1 hour and have an adverse reaction will return to 2 hourly infusions. Name must be less than 100 characters 2015 Jun;24(2):165-70. doi: 10.15403/jgld.2014.1121.242.tezz.Mazzuoli S, Tricarico D, Demma F, Furneri G, Guglielmi FW.PLoS One. Prior to Initiating Diltiazem Infusion: BMP with Mg if one has not been drawn in the past 24 hours. Clipboard, Search History, and several other advanced features are temporarily unavailable. Guideline for the use of Infliximab (Remicade ®) in patients with Inflammatory Bowel Disease (IBD) Page | 7 Infusion reaction All infusion reactions will be dealt with according to the Infusion reaction protocol (Refer to appendix 3). Continuous cardiac monitoring with documentation of rhythm requiring intervention. Epub 2015 Oct 6. Wolters Kluwer Standard Infusion: 125 mg in Normal Saline 125 mL (1 mg/ mL) (Mix five 25 mg/5 mL vials in NS 100 mL, total volume 125 mL containing 125 mg) Dosage: Initial Bolus - 0.25 mg/kg over 2 minutes (5 mg/ mL 5 mL vials in refrigerator) 40 kg…10 mg (2 mL) 60 kg…15 mg (3 mL) 70 kg…17.5 … Please enable it to take advantage of the complete set of features!
Clare DF, Alexander FC, Mike S, Dan G, Allan F, Lisa W, Peter HJ.Eur J Gastroenterol Hepatol.
doi: 10.1371/journal.pone.0166443. 2009 Jan;21(1):71-5. doi: 10.1097/MEG.0b013e3283081afe. Epub 2011 Apr 21.Dig Dis Sci.
Epub 2016 Sep 23. eCollection 2019 Jan-Feb.Frontline Gastroenterol. Springer Springer Please enable it to take advantage of the complete set of features! 2008 Dec;31(10):629-32. doi: 10.1016/S0210-5705(08)75809-6.
COVID-19 is an emerging, rapidly evolving situation. 2016 Nov 16;11(11):e0166443.